Adam Fein, founder of Drug Channels, said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.
HMP Global, a healthcare education company, will acquire Drug Channels Institute. Founded in 2006 by Adam J. Fein, Ph.D., Drug Channels is a market intelligence company focused on the pharmaceutical industry. It provides webinars and industry reports on pharmaceutical economic issues and drug supply and distribution. Terms of the agreement were not disclosed.
As part of the integration, Drug Channels leadership will remain in place, with Fein becoming president, Drug Channels Institute, and Paula Fein assuming the role of vice president, business development.
Adam Fein is a well-known thought leader in the pharmaceutical industry providing insight and analysis on drug pricing, pharmacy benefit managers, the specialty drug market, drug reimbursement, and healthcare reform. He is known for his humor in making the industry more accessible for readers.
On a blog post on the Drug Channels website, Adam Fein said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.
HMP produces in person and virtual medical education events and provides news and clinical information for healthcare providers. It produces about 50 journals/websites and 400 events and serves oncology, neurology, psychiatry and behavioral health, gastroenterology, cardiovascular, dermatology and rheumatology.
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More